Trade Chromadex Corp - CDXC CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0266 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024124% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001901% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 7.4917 |
| Open | 7.4117 |
| 1-Year Change | 419.75% |
| Day's Range | 7.4117 - 7.7817 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 21, 2024 | 7.6117 | 0.0600 | 0.79% | 7.5517 | 7.8317 | 7.3517 |
| Nov 20, 2024 | 7.4917 | 0.0000 | 0.00% | 7.4917 | 7.5917 | 7.2317 |
| Nov 19, 2024 | 7.5117 | 0.3600 | 5.03% | 7.1517 | 7.6517 | 7.0617 |
| Nov 18, 2024 | 7.2617 | 0.3500 | 5.06% | 6.9117 | 7.3717 | 6.8317 |
| Nov 15, 2024 | 6.8017 | -0.1900 | -2.72% | 6.9917 | 7.0717 | 6.7917 |
| Nov 14, 2024 | 7.1817 | 0.1500 | 2.13% | 7.0317 | 7.4017 | 6.8117 |
| Nov 13, 2024 | 6.9917 | -0.2700 | -3.72% | 7.2617 | 7.5217 | 6.9617 |
| Nov 12, 2024 | 7.2417 | 0.2400 | 3.43% | 7.0017 | 7.5617 | 7.0017 |
| Nov 11, 2024 | 7.0017 | 0.5400 | 8.36% | 6.4617 | 7.0117 | 6.2017 |
| Nov 8, 2024 | 6.4817 | -0.1300 | -1.97% | 6.6117 | 6.7617 | 6.3817 |
| Nov 7, 2024 | 6.7517 | -0.1900 | -2.74% | 6.9417 | 6.9917 | 6.7017 |
| Nov 6, 2024 | 6.9717 | 0.6400 | 10.11% | 6.3317 | 7.0617 | 6.1117 |
| Nov 5, 2024 | 6.0917 | 0.4000 | 7.03% | 5.6917 | 6.3617 | 5.5217 |
| Nov 4, 2024 | 5.7417 | 0.0800 | 1.41% | 5.6617 | 6.1617 | 5.3517 |
| Nov 1, 2024 | 5.8517 | 1.7200 | 41.63% | 4.1317 | 5.9417 | 3.7917 |
| Oct 31, 2024 | 3.4817 | -0.0700 | -1.97% | 3.5517 | 3.5917 | 3.4717 |
| Oct 30, 2024 | 3.5617 | -0.0500 | -1.38% | 3.6117 | 3.6617 | 3.4917 |
| Oct 29, 2024 | 3.6017 | 0.0200 | 0.56% | 3.5817 | 3.6617 | 3.5417 |
| Oct 28, 2024 | 3.6517 | 0.2100 | 6.10% | 3.4417 | 3.7017 | 3.4417 |
| Oct 25, 2024 | 3.4617 | 0.0100 | 0.29% | 3.4517 | 3.5617 | 3.4417 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Chromadex Corp Company profile
About Chromadex Corp
ChromaDex Corp. is a global bioscience company, which is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. NAD+ is a coenzyme and a regulator of cellular metabolism. It operates through three segments: Consumer products, Ingredients, and Analytical reference standards and services segment. The Consumer products segment provides finished dietary supplement products that contain the ingredients directly to consumers as well as to distributors. The Ingredients segment develops and commercializes ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Analytical reference standards and services segment supplies phytochemical reference standards and other research and development services. Its ingredients include Tru Niagen and Immulina. The Tru Niagen is a form nicotinamide riboside (NR). NR is a member of the vitamin B3 family. Immulina is a spirulina extract.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Chromadex Corp revenues increased 14% to $67.4M. Net loss increased 36% to $27.1M. Revenues reflect Consumer Products Segments increase of 20% to $56.7M, Analytical Reference Standards and Service segment increase of 12% to $3.3M. Higher net loss reflects Corporate and other segment loss increase of 19% to $36.4M, Ingredients Segments income decrease of 27% to $3.7M.
Equity composition
Common Stock $.001 Par, 08/11, 150M auth., 60,875,325 issd. Insiders & Strategic holders own 45.88%. 04/16, 1-for-3 recerse stock split.
| Industry: | Biotechnology & Medical Research (NEC) |
10900 Wilshire Blvd
Suite 600
LOS ANGELES
CALIFORNIA 90024
US
News
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
15:17, 18 November 2024
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com